CL2022003755A1 - Muteínas de il-10 y proteínas de fusión de las mismas - Google Patents

Muteínas de il-10 y proteínas de fusión de las mismas

Info

Publication number
CL2022003755A1
CL2022003755A1 CL2022003755A CL2022003755A CL2022003755A1 CL 2022003755 A1 CL2022003755 A1 CL 2022003755A1 CL 2022003755 A CL2022003755 A CL 2022003755A CL 2022003755 A CL2022003755 A CL 2022003755A CL 2022003755 A1 CL2022003755 A1 CL 2022003755A1
Authority
CL
Chile
Prior art keywords
muteins
antigen
fusion proteins
compositions
trem
Prior art date
Application number
CL2022003755A
Other languages
English (en)
Inventor
Hsu Hailing
Foltz Ian
Mock Marissa
Mitch Luna Victor
Zhang Ming
Wannberg Sharon
Ozlem CAMDERE TAPIA Gamze
P Riley Timothy
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2022003755A1 publication Critical patent/CL2022003755A1/es

Links

Classifications

    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02J—CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
    • H02J50/00—Circuit arrangements or systems for wireless supply or distribution of electric power
    • H02J50/005—Mechanical details of housing or structure aiming to accommodate the power transfer means, e.g. mechanical integration of coils, antennas or transducers into emitting or receiving devices
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Power Engineering (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente divulgación se refiere, en general, a muteínas de IL-10 que son estables como monómeros, a proteínas de unión a antígeno que se unen a TREM-1 y a proteínas de unión a antígeno que comprenden muteínas de IL-10 y restos de unión a antígeno, por ejemplo, anticuerpos anti-TREM-1 y composiciones de las mismas. La divulgación también proporciona métodos de tratamiento de enfermedades inflamatorias, tales como enteropatía inflamatoria o colitis ulcerosa, usando las composiciones.
CL2022003755A 2020-06-26 2022-12-26 Muteínas de il-10 y proteínas de fusión de las mismas CL2022003755A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063045041P 2020-06-26 2020-06-26
US202063199218P 2020-12-14 2020-12-14

Publications (1)

Publication Number Publication Date
CL2022003755A1 true CL2022003755A1 (es) 2023-07-21

Family

ID=77071744

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022003755A CL2022003755A1 (es) 2020-06-26 2022-12-26 Muteínas de il-10 y proteínas de fusión de las mismas

Country Status (16)

Country Link
US (1) US20230265145A1 (es)
EP (1) EP4172184A2 (es)
JP (1) JP2023531493A (es)
KR (1) KR20230027300A (es)
CN (1) CN116209459A (es)
AU (1) AU2021296917A1 (es)
CA (1) CA3187576A1 (es)
CL (1) CL2022003755A1 (es)
CO (1) CO2023000431A2 (es)
CR (1) CR20230025A (es)
IL (1) IL299149A (es)
MX (1) MX2022016548A (es)
PE (1) PE20231082A1 (es)
TW (1) TW202216743A (es)
UY (1) UY39298A (es)
WO (1) WO2021263167A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116425857B (zh) * 2023-06-09 2023-08-18 苏州依科赛生物科技股份有限公司 一种无糖基化修饰的il-15及制备方法
CN117143235B (zh) * 2023-10-26 2024-02-09 中国科学院苏州纳米技术与纳米仿生研究所 一种单克隆抗体及应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
EP0904107B1 (en) 1996-03-18 2004-10-20 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
ES2301183T3 (es) 1996-12-03 2008-06-16 Amgen Fremont Inc. Anticuerpo completamente humano que se une al receptor del egfr.
DE19851675A1 (de) * 1998-11-10 2000-05-11 Bayer Ag Menschliche Interleukin-10 Mutantenproteine
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
CA2383456C (en) 1999-08-23 2016-06-07 Clive Wood Pd-1, a receptor for b7-4, and uses therefor
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
AU2003288675B2 (en) 2002-12-23 2010-07-22 Medimmune Limited Antibodies against PD-1 and uses therefor
EP1591527B1 (en) 2003-01-23 2015-08-26 Ono Pharmaceutical Co., Ltd. Substance specific to human pd-1
CN109485727A (zh) 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
MX2007015942A (es) 2005-07-01 2008-03-07 Medarex Inc Anticuerpos monoclonales humanos para ligandos 1 (pd-l1) de muerte programada.
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
DK2170959T3 (da) 2007-06-18 2014-01-13 Merck Sharp & Dohme Antistoffer mod human programmeret dødsreceptor pd-1
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
AU2009290544B2 (en) 2008-09-12 2015-07-16 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
CN102264762B (zh) 2008-09-26 2018-03-27 达纳-法伯癌症研究公司 人抗pd‑1、pd‑l1和pd‑l2的抗体及其应用
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
TWI686405B (zh) 2008-12-09 2020-03-01 建南德克公司 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途
EP3192811A1 (en) 2009-02-09 2017-07-19 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
US9657081B2 (en) 2012-09-07 2017-05-23 Inserm (Institut National De La Sante Et De La Recherche Medicale) Inhibiting peptides derived from triggering receptor expressed on myeloid cells-1 (TREM-1) TREM-like transcript 1 (TLT-1) for treatment of cardiovascular diseases
EP2989240A4 (en) * 2013-04-24 2016-10-19 Armo Biosciences Inc INTERLEUKIN-10 COMPOSITIONS AND USES THEREOF
PL3369435T3 (pl) * 2013-07-18 2020-04-30 Xalud Therapeutics, Inc. Kompozycja do leczenia choroby zapalnej stawów
ES2792183T3 (es) 2013-09-13 2020-11-10 Beigene Switzerland Gmbh Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico
CN106061997A (zh) * 2014-02-06 2016-10-26 豪夫迈·罗氏有限公司 白介素‑10免疫缀合物
WO2017152102A2 (en) * 2016-03-04 2017-09-08 Alector Llc Anti-trem1 antibodies and methods of use thereof
CR20210319A (es) 2018-01-12 2021-07-27 Amgen Inc ANTICUERPOS ANTI-PD-1 Y MÉTODOS DE TRATAMIENTO (Div. 2020-330)

Also Published As

Publication number Publication date
CN116209459A (zh) 2023-06-02
WO2021263167A2 (en) 2021-12-30
PE20231082A1 (es) 2023-07-17
CA3187576A1 (en) 2021-12-30
TW202216743A (zh) 2022-05-01
UY39298A (es) 2022-01-31
EP4172184A2 (en) 2023-05-03
CR20230025A (es) 2023-10-05
MX2022016548A (es) 2023-03-14
WO2021263167A3 (en) 2022-04-21
KR20230027300A (ko) 2023-02-27
CO2023000431A2 (es) 2023-03-27
US20230265145A1 (en) 2023-08-24
IL299149A (en) 2023-02-01
AU2021296917A1 (en) 2023-02-02
JP2023531493A (ja) 2023-07-24

Similar Documents

Publication Publication Date Title
CO2023000431A2 (es) Muteínas de il-10 y proteínas de fusión de las mismas
CL2021002994A1 (es) Anticuerpos nuevos que se unen específicamente a los epítopos del virus del zika y usos de los mismos. (divisional de la solicitud no. 201900067)
PE20181451A1 (es) Anticuerpos neutralizadores del virus de inmunodeficiencia humana
ECSP19026304A (es) Anticuerpos de unión a cd3
HRP20200034T1 (hr) Monoklonska protutijela protiv čimbenika rasta i diferencijacije 15 (gdf-15), te njihova upotreba u liječenju kaheksije uzrokovane rakom i raka
EA201891178A1 (ru) Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
GT201300149A (es) Proteinas de union al tnf-a
MX2018016404A (es) Anticuerpos de union a cd3.
MX2015012540A (es) Ratón de cadena ligera común.
EA201590208A1 (ru) Усиление активности т-клеток car путем совместного введения биспецифического антитела
PE20081478A1 (es) Anticuerpos cd44
EA201491569A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С СИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
EA201691925A1 (ru) Биспецифические антитела, которые связываются с cd38 и cd3
PE20090993A1 (es) Anticuerpos anti-cxcr5 humanizados y derivados de los mismos
PE20140882A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
EA201990285A1 (ru) Гетеродимерные иммуноглобулиновые конструкции и способы их получения
PE20190920A1 (es) Anticuerpos modificados de union a fcrn humano y metodos de utilizacion
PE20211767A1 (es) Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y metodos de uso de anticuerpos anti-hla-g
EA201491571A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С АСИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
MX357308B (es) Ratones que expresan un repertorio limitado de cadena ligera de inmunoglobulina.
EA201600276A1 (ru) Анти-il-17-антитела, способ их получения и способ применения
EA201590459A1 (ru) Специфические антитела к островковому амилоидному полипептиду человека (hiapp) и их применение
PE20161210A1 (es) Anticuerpos anti-mcam y metodos de uso asociados
EA201991912A1 (ru) Составы, содержащие pd-1-связывающие белки, и способы их получения
EA201992460A1 (ru) Антитела-агонисты btla и их применение